Novartis India Ltd (NOVARTIND)
₹1,641.20
Mkt cap
₹4,052 Cr
P/E ratio
41.40
P/B
4.96
Div yield
1.52%
ROE
11.60%
ROCE
16.20%
EPS (TTM)
₹39.64
Book value
₹331
52W range
557–1,702
Sector
Healthcare
Novartis India Ltd is primarily engaged in the Business of Wholesale of pharmaceuticals and medical goods. [1] It imports various medicines to India from different sources across the globe. [2]
Health check
Mixed
ValuationFair
ProfitabilityAverage
GrowthLow
TechnicalsBullish
52-week range
−3.57% from high₹1,641
₹557+194.81% from low₹1,702
Current
₹1,641.20
Prev close
₹1,658.00
Day
−1.01%
Price performance
1D
−1.01%
1W
−1.60%
1M
+14.38%
3M
+70.60%
6M
+125.50%
1Y
+158.78%
YTD
+64.87%
Financials
FRevenue, profit & margin
P/E ratio
41.4×
NOVARTIND is 22% above the sector median of 34.0×
NOVARTIND41.4×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 91 | 79 | 85 | 81 | 92 | 87 | 93 | 84 | 88 | 90 | 86 | 91 | 104 | |
| Expenses | 73 | 62 | 65 | 70 | 68 | 69 | 67 | 60 | 60 | 66 | 64 | 70 | 69 | |
| Operating Profit | 17 | 17 | 20 | 11 | 24 | 18 | 26 | 24 | 27 | 24 | 22 | 21 | 35 | |
| OPM % | 19% | 21% | 23% | 14% | 26% | 21% | 28% | 29% | 31% | 26% | 26% | 23% | 34% | |
| Other Income | 12 | 17 | 22 | 10 | 10 | 10 | 11 | 11 | 11 | 9 | 9 | 10 | 9 | |
| Interest | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | |
| Depreciation | 2 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | |
| Profit before tax | 28 | 32 | 41 | 21 | 34 | 28 | 35 | 34 | 37 | 33 | 30 | 30 | 43 | |
| Tax % | 27% | 27% | 36% | 31% | 24% | 26% | 28% | 14% | 26% | 26% | 46% | 16% | 25% | |
| Net Profit | 20 | 24 | 27 | 15 | 26 | 20 | 25 | 29 | 28 | 24 | 16 | 25 | 32 | |
| EPS in Rs | 8.21 | 9.59 | 10.76 | 5.95 | 10.42 | 8.27 | 10.31 | 11.87 | 11.19 | 9.81 | 6.52 | 10.23 | 13.05 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Jun 202670.68%Promoter
Promoters70.68%
FIIs0.16%0.01
DIIs1.35%0.82
Public27.81%0.79
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,735 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.11 | 1,88,720 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,546 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Novartis India | ₹1,641.20 | 41.45 | 4,052 | 1.52% | 32 | +16.62% | 104 | +18.57% | 16.25% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports15
Financial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013bseFinancial Year 2012bseFinancial Year 2011bse
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 14h - Intimation of Newspaper Advertisement by Novartis India Limited ("the Company") regarding the publication of Unaudited Financial Results of the Company for the Quarter ended June …Financial Results Of Novartis India Limited For The Quarter Ended June 30, 2026. 1dBoard Meeting Outcome for Outcome Of The Meeting Of The Board Of Novartis India Limited Held On Thursday, July 23, 2026. 1d - Board approved unaudited Q1 FY2027 results for quarter ended June 30, 2026.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 13 Jul - Submitted Regulation 74(5) compliance certificate for quarter ended June 30, 2026.Post-Offer advertisement 10 Jul - Post-offer ad: WaveRise/ChrysCapital offer for 64,19,608 shares at ₹860.64; only 40 shares accepted.